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1. Introduction
Although the primary consequences of cerebral palsy (CP) are
associated with brain insults, people with CP who experience
impaired physical activity often experience musculoskeletal
problems [1,2], particularly bone loss in adulthood owing to
accumulative paralysis and impaired weight bearing resulting
from mechanical adaptations [3,4]. Bone loss in adults with CP
probably occurs at an early age, thus leading to aggravated
symptoms as problems accumulate into adulthood [5]. Eventually,
adults with CP commonly experience atypical fragility fractures
and unfavourable prognoses such as malunion after musculoskel-
etal surgeries [3,6].
Despite the serious complications, a standard therapy has not
been established for bone loss in CP [3]. Pharmacological inter-
ventions such as bisphosphonate and intermittent exposure to
parathyroid hormone have been introduced to manage bone health
in CP [7,8]. However, therapeutic mechanisms are inappropriate as
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A B S T R A C T
Background: Individuals with cerebral palsy (CP) experience bone loss due to impaired weight bearing.
Despite serious complications, there is no standard medication.
Objective: To develop a new pharmacological agent, we performed a series of studies. The primary aim
was to develop an animal model of CP to use our target medication based on transcriptome analysis of
individuals with CP. The secondary aim was to show the therapeutic capability of collagen-binding
peptide (CBP) in reversing bone loss in the CP mouse model.
Methods: A total of 119 people with CP and 13 healthy adults participated in the study and 140 mice were
used for the behavioral analysis and discovery of therapeutic effects in the preclinical study. The mouse
model of CP was induced by hypoxic-ischemic brain injury. Inclusion and exclusion criteria were
established for CBP medication in the CP mouse model with bone loss.
Results: On the basis of clinical outcomes showing insufficient mechanical loading from non-ambulatory
function and that underweight mainly affects bone loss in adults with CP, we developed a mouse model
of CP with bone loss. Injury severity and body weight mainly affected bone loss in the CP mouse model.
Transcriptome analysis showed SPP1 expression downregulated in adults with CP who showed lower
bone density than healthy controls. Therefore, a synthesized CBP was administered to the mouse model.
Trabecular thickness, total collagen and bone turnover activity increased with CBP treatment as
compared with the saline control. Immunohistochemistry showed increased immunoreactivity of runt-
related transcription factor 2 and osteocalcin, so the CBP participated in osteoblast differentiation.
Conclusions: This study can provide a scientific basis for a promising translational approach for
developing new anabolic CBP medication to treat bone loss in individuals with CP.




www.sciencedirect.com* Corresponding author at: Department and Research Institute of Rehabilitation
Medicine, Yonsei University College of Medicine, 50–1, Yonsei-ro, Seodaemun-gu,
03722 Seoul, Republic of Korea.
E-mail address: srcho918@yuhs.ac (S.-R. Cho).
https://doi.org/10.1016/j.rehab.2020.09.009
1877-0657/C 2020 The Authors. Published by Elsevier Masson SAS. This is an open acces
nd/4.0/).lifelong medications in CP because those indications are more
specific for osteogenesis imperfecta [9,10], postmenopausal
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ith CP [14].
To develop a new pharmacological agent and therapeutic
trategy, we performed a series of translational studies. First,
ignificant clinical factors affecting bone health were identified in
ndividuals with CP, then transcriptome analysis was conducted to
dentify imbalanced gene expression in people with CP as
ompared with normal controls. Second, a mouse model of CP
ith bone loss was developed by using modified neonatal hypoxic-
schemic (HI) brain-injured mice based on the preceding clinical
utcomes. Finally, from transcriptome analyses, a novel treatment
sing synthesized collagen-binding peptide (CBP) of osteopontin
as administered to treat the mouse model of CP with bone loss.
he research hypothesis was that a complex interplay of severe
rain injury, low body weight, insufficient mechanical loading, and
educed muscle force affects overall bone health in CP. The clinical
elevance of administering CBP might be determined by mimicking
uman-like features in an animal model of CP with bone loss. This
tudy could provide a scientific basis for a promising translational
pproach to treating bone loss in people with CP.
. Materials and methods
.1. Study approval
This study was approved by the Institutional Review Board (No.
-2012-0751; 4-2013-0404) of Yonsei University Health System.
nformed consent was acquired from all participants, who agreed
o the procedures in the prospective study. All research procedures
ere approved by the Institutional Animal Care and Use
ommittee of Yonsei University College of Medicine (IACUC No.
016-0019; 2018-0277) [15].
.2. Clinical outcome variables in patients with CP
A total of 125 patients from our hospital were recruited from
007 to 2015 for the present retrospective study. Six patients were
xcluded for reasons such as missing height and femur bone
ensity data. In total, 47 patients with missing data including
unctional outcomes were excluded from the regression analyses.
inally, 72 outcome variables including age, body weight, Modified
arthel Index (MBI), grip strength, and ambulatory function were
sed for regression analysis. Linear regression analysis of the
linical parameters was used to find the most significant clinical
isk factors associated with bone health. The MBI was used to
dentify functional level from activities of daily living. Grip
trength was used to identify the maximal force when holding a
ynamometer.
To identify regional BMD based on ambulatory status and body
eight classified by body mass index (BMI), 4 groups of CP
articipants were distinguished: ambulatory and normal weight
n = 55), ambulatory and underweight (n = 8), non-ambulatory and
ormal weight (n = 39), and non-ambulatory and underweight
n = 17). Participants were also classified based on ambulatory
tatus (ambulatory and non-ambulatory) and CP type (spastic and
yskinetic) determined as in a previous study [3].
.3. Participants in transcriptome analysis
The number of individuals in the transcriptomic analysis could
not be matched with regression analysis (n = 72) owing to
agreement with the prospective study and sample use. After
screening medical records, participants who were ineligible in
this study were excluded based on previously described
criteria: age < 20 years; previous medication affecting bone
metabolism within 1 year, such as anticonvulsant, bisphos-
phonate, glucocorticoid; any illness affecting bone metabolism,
such as bone tumor, hyperparathyroidism, Cushing’s syndrome,
and rheumatoid arthritis; and systemic disease such as
diabetes, kidney, liver and thyroid disease [3]. Clinical cha-
racteristics of participants with CP and age-matched healthy
controls included are in Table 3.
2.4. Neonatal hypoxic-ischemic (HI) brain injury
To develop an animal model mimicking features of individuals
with CP, we used a modified Rice–Vannuci HI model [16]. By using
a ventral neck incision and exposure of the right common carotid
artery at the mid-tracheal level, 7-day-old CD-1 mice underwent
permanent ischemic brain injury induced by unilateral ligation of
the common carotid artery under anaesthesia with isoflurane.
After a 2-hr recovery, mice underwent 8% O2 hypoxic conditions for
90 min in a chamber maintained at 37.5 8C. The mice then returned
to their dams under normal air conditions [15].
2.5. Inclusion and exclusion criteria for therapeutic application
The inclusion and exclusion criteria were established to
identify the effects of the CBP treatment on mice with bone loss
after neonatal HI brain injury. The patent number is 10-2019-
0016496 (Korea). Two main factors were considered based on
linear regression analyses, severity of the brain injury and body
weight. HI brain-injured mice at age 2 weeks were classified as
having severe and mild HI and mild brain-injured mice were
excluded. Mice with body weight < 24.4 g for females
and < 31.5 g for males at 6 weeks of age were included, and mice
with body weight within the normal range were excluded. Finally,
animals regularly showing hyperactive behaviour such as turning
around or rearing repetitively, were excluded from the therapeu-
tic timeline (Fig. 2A–C) [17].
2.6. Synthesis of the CBP
Osteopontin residues 150–168 had the strongest binding
affinity to collagen. The sequence was synthesized with a peptide
synthesizer (Apex 396; AAPP Tec, Louisville, KY, USA) from a
pharmaceutical firm (NIBEC, Seoul, Korea) as described
[18,19]. The purity of the peptides was confirmed to be > 98%
(Fig. 2D).
2.7. Therapeutic strategy in an animal model of CP
Neonatal HI brain-injured mice with bone loss (severe brain
injury  low body weight) were included in accordance with the
inclusion and exclusion criteria. From these criteria, mice were
randomly allocated to CBP treatment or saline control. The CBP
treatment group was subcutaneously injected with a high
concentration of CBP peptides (600 mg per mouse) biweekly for
2 months beginning at 8 weeks of age (Fig. 2C) [19]. OtherTo propose an optimized bone anabolic agent for people with
P, pathophysiological factors imbalanced in individuals with
P versus healthy adults were analysed by transcriptome
nalysis. From 2013 to 2015, 26 participants (13 with CP and
3 healthy adults) agreed to participate in gene expression
creening at the mRNA level as a prospective analysis (Table 3).2
procedures are described in the Online material.
2.8. Statistical analysis
All statistical analyses were performed with SPSS Statistics 23
(IBM Corp., Armonk, NY, USA). Regression analysis was performed
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Stepwise multivariate analysis was performed to investigate
factors associated with regional BMD. Chi2 test was used to
compare 2 groups. ANOVA was followed by Fisher’s LSD post hoc
test for comparing  3 groups. A two-way ANOVA with one
repeated measure was used to test the interaction between time
and groups (6  3 mixed design), as well as the main effect
between groups. The time effect was not considered in this study
because bone growth in rodents continues after sexual maturity
[20]. An independent t-test was used to compare the difference
between 2 groups. P < 0.05 was considered statistically significant.
An a priori analysis was used to estimate sample size with the
effect size based on a previous study [21], showing a medium-to-
large effect size in postmenopausal women: 58 participants were
required to provide a minimum of 80% statistical power to detect
factors associated with BMD on linear multiple regression analysis.
With a very large effect size (approximately f2 = 1.0) in mice in this
study, we needed 20 mice to provide a minimum of 80% statistical
power.
3. Results
3.1. Risk factors associated with bone health in individuals with CP
The mean (SD) age of the 72 individuals with CP was 39.5 (11.1)
years, height was 158.8 (6.5) cm, weight 55.0 (9.8) kg, and BMI
21.8 (3.7) kg/m2. Linear regression analysis to find the most
significant clinical risk factors associated with bone loss in
individuals with CP revealed ambulatory function as the most
influential factor associated with lumbar spine, femur intertro-
chanter, and total hip BMD. Body weight was also a significant
factor (Table 1).
3.2. Bone density based on ambulatory status and body weight
Clinical characteristics of 119 participants with CP are shown in
Table 2. The 4 groups differed in lumbar spine BMD (Z-scores; F(3,
115) = 3.870; P = 0.011), femur neck BMD (F(3, 115) = 7.615;
P < 0.001), femur intertrochanter BMD (F(3, 115) = 12.641;
Table 2
Demographic and clinical parameters in the clinical study by categories of CP (n = 119).












Age (years) 39.4 (11.2) 39.5 (8.8) 39.0 (10.7) 36.9 (12.8)
Height (cm) 159.4 (7.6) 158.1 (8.5) 158.5 (7.4) 159.7 (8.9)
Weight (kg) 57.5 (10.0) 42.6 (6.8)y 56.6 (6.3) 41.6 (5.5)*
Body mass index (kg/m2) 22.6 (3.2) 17.0 (1.2)y 22.6 (2.4) 16.4 (2.0)*
Table 1
Clinical factors associated with skeletal bone mineral density (BMD) in individuals with cerebral palsy (CP) (n = 72).




Coefficient (SE) P-value Coefficient (SE) P-value Coefficient (SE) P-value
Lumbar spine Sex (female) 0.361 (0.279) 0.201 – – – –
Body weight 0.025 (0.014) 0.089 – – – –
Modified Barthel Index 0.012 (0.005) 0.030* – – – –
Grip strength 0.010 (0.005) 0.028* – – – –
Ambulation (non-ambulator) 0.818 (0.270) 0.003* – – 0.818 (0.270) 0.003*
Femur neck Sex (female) 0.079 (0.263) 0.764 – – – –
Body weight 0.036 (0.013) 0.007* 0.032 (0.012) 0.012* – –
Modified Barthel Index 0.015 (0.005) 0.004* 0.013 (0.005) 0.007* 0.015 (0.005) 0.004*
Grip strength 0.007 (0.004) 0.126 – – – –
Ambulation (non-ambulator) 0.649 (0.256) 0.013* – – – –
Femur intertrochanter Sex (female) 0.420 (0.266) 0.119 – – – –
Body weight 0.030 (0.014) 0.032* 0.027 (0.013) 0.033* – –
Modified Barthel Index 0.017 (0.005) 0.001* – – – –
Grip strength 0.012 (0.004) 0.006* – – – –
Ambulation (non-ambulator) 0.894 (0.253) 0.001* 0.866 (0.247) 0.001* 0.894 (0.253) 0.001*
Total hip Sex (female) 0.374 (0.264) 0.161 – – – –
Body weight 0.035 (0.013) 0.010* 0.033 (0.012) 0.010* – –
Modified Barthel Index 0.016 (0.005) 0.002* – – – –
Grip strength 0.012 (0.004) 0.009* – – – –
Ambulation (non-ambulator) 0.823 (0.253) 0.002* 0.790 (0.244) 0.002* 0.823 (0.253) 0.002*
Grip strength (percentage normalized based on age- and sex-matched strength of healthy adults); SE: standard error; R2 = 0.116, adjusted R2 = 0.104 in the analysis of the
lumbar spine BMD; R2 = 0.110, adjusted R2 = 0.098 for femur neck BMD; R2 = 0.151, adjusted R2 = 0.139 for femur intertrochanter BMD; R2 = 0.131, adjusted R2 = 0.118 for total
hip BMD; *: P < 0.05 based on linear regression analyses.Sex (male/female) 28/27 2/6 23/16 9/8
Type (spastic/dyskinetic) 19/36 1/7 22/17 7/10
Bone status§ (normal/osteopenia/osteoporosis) 26/23/6 3/5/0 6/20/13 1/4/12
Data are mean (SD). *: P < 0.05 comparing non-ambulatory and underweight vs. non-ambulatory and normal weight; non-ambulatory and underweight vs. ambulatory and
normal weight); y: P < 0.05 comparing ambulatory and underweight vs. non-ambulatory and normal weight; ambulatory and underweight vs. ambulatory and normal weight
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tatistical outcomes are shown in Fig. 1.
.3. The top-ranked gene based on transcriptome analysis
The transcriptome database was used to identify dysregulated
ene expression associated with bone metabolism. BMD z-scores
or the femur neck and total hip were lower for participants with
P than healthy controls (Table 3). Finally, the focus was on the
op-ranked gene, secreted phosphoprotein 1 (SPP1), which was
ignificantly downregulated, showing 70.1-fold change in mRNA
evel in individuals with CP versus healthy adults (Online material
able 1).
.4. Impaired muscle force in an animal model of CP
Contralateral forelimb analysis showed significantly decreased
rip strength in severely brain-injured mice versus both mildly
rain-injured mice and normal mice (F(2, 123) = 28.733; P < 0.001,
ost hoc comparison after one-way ANOVA; Fig. 2E).
.5. Linear regression analysis of factors critical for bone loss
From univariate analysis of whole-skeletal BMD, the severity of
rain injury, body weight, contralateral forelimb grip strength, and
the number of rearing instances were significantly correlated in
the CP model. The results for lumbar spine, affected femur and
humerus BMD are in Table 4. In the final stepwise model, severity
of brain injury was the most influential factor for both whole-
skeletal and lumbar-spine BMD. Body weight was associated the
most with both affected femur and humerus BMD.
3.6. Bone loss in mice with neonatal HI brain injury
From the criteria established by linear regression analyses,
severely brain-injured mice with low body weight showed the
lowest skeletal BMD in whole-body skeleton, lumbar spine from
L1–L5, affected femur and affected humerus as compared with
mild or severely brain-injured mice with normal body weight in
adulthood.
Analysis of the whole-skeletal BMD revealed no significant
time  group interaction (Wilk’s lambda = 0.745; F(10, 78) = 1.234;
P = 0.283). The main effect of group (F(2, 43) = 13.715; P < 0.001)
was observed by two-way repeated-measures ANOVA (Fig. 2F).
Analysis of the lumbar spine BMD revealed no significant
time  group interaction (Wilk’s lambda = 0.576; F(10,
78) = 2.477; P = 0.124). The main effect of group (F(2, 43) = 10.565;
P < 0.001) was significant.
Analysis of the affected femur BMD revealed no significant
time  group interaction (Wilk’s lambda = 0.924; F(10, 78) = 0.316;
P = 0.975). The main effect of group (F(2, 43) = 8.818; P = 0.001) was
significant. Similarly, analysis of the affected humerus BMD
revealed no significant time  group interaction (Wilk’s lamb-
da = 0.819; F(10, 78) = 0.821; P = 0.609). The main effect of group
(F(2, 43) = 24.888; P < 0.001) was significant.
3.7. Effect of CBP treatment on bone loss
A representative 3-D image of skeletal bone showed trabecular
bone density improved in the CBP treatment group versus the
saline control. Micro-CT (mCT) analysis of skeletal bone confirmed
that trabecular thickness in the femora (P = 0.023, independent t-
ig. 1. Significant differences in bone mineral density (BMD) of the lumbar spine and femur based on ambulatory status and body weight of individuals with cerebral palsy
CP). Sample size (ambulatory and normal weight CP, n = 55; ambulatory and underweight CP, n = 8; non-ambulatory and normal weight CP, n = 39; non-ambulatory and
nderweight CP, n = 17); data are mean  SD; *: P < 0.05 based on post hoc comparison after one-way ANOVA.
able 3
aseline characteristics of participants in transcriptome analyses.






Age (years) 34.4 (7.3) 39.5 (8.0)
Height (cm) 168.3 (8.8) 159.0 (7.7)*
Weight (kg) 60.5 (13.4) 55.8 (8.7)






Sex [male/female (n)] 4/9 6/7
Type [spastic/dyskinetic (n)] NA 6/7Ambulatory status
[independent/wheelchair (n)]
13/0 7/6
Bone status [normal/osteopenia/osteoporosis (n)] 13/0/0 3/6/4
Lumbar spine BMD (z-score) 0.3 (0.7) 0.5 (1.6)
Femur neck BMD (z-score) 0.2 (0.5) 0.7 (1.1)*
Total hip BMD (z-score) 0.6 (1.1) 1.2 (0.9)*
ata are mean (SD). NA: not associated; *: P < 0.05 based on independent t-test.
4
test) and humeri (P = 0.040) of CBP-treated mice was significantly
increased as compared with the saline control (Fig. 3A and B). Total
collagen content was significantly improved in the cortical- and
trabecular-containing region in the CBP treatment group versus
the saline control group (F(2,15) = 9.036; P = 0.003, post hoc
comparison after one-way ANOVA; Fig. 3C and D).
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Mice were sacrificed and serum samples were used to identify the
effect of CBP on bone turnover activity. Both PINP (P = 0.018,
independent t-test) and CTX-I (P = 0.020) were highly upregulated in
including runt-related transcription factor 2 (RUNX2) and osteo-
calcin (OCN), were detected on immunohistochemistry. The
expression of RUNX2 was higher in the CBP treatment than saline
control group (P = 0.005, independent t-test; Fig. 3G and H).
The expression of OCN was also higher in the CBP treatment than
Figure 2. Experimental timeline for therapeutic intervention in an animal model of CP with bone loss. A. Post-mortem assessment to confirm injury severity. B. Determined
infarct size and comparison of lesion locations between mild brain injuries and severe brain injuries on MRI. C. Summarized experimental procedures from birth to 16 weeks
of age. D. Sequences of the collagen-binding peptide (CBP) of osteopontin. E. Hemiplegic motor impairments in severely brain-injured mice. F. Bone loss in severely brain-
injured mice with low body weight. A statistically significant group effect was confirmed (P < 0.05) based on a two-way repeated measures ANOVA in whole body skeleton,
lumbar spine, affected femur, and affected humerus. Data are mean  SD. E. Sample size (normal, n = 12; mild brain injury, n = 18; severe brain injury, n = 96); *: P < 0.05 based on
post hoc comparison after one-way ANOVA. F. Sample size (mild brain injury, n = 18; severe brain injury  normal body weight, n = 22; severe brain injury  low body weight, n = 6);
*: P < 0.05 comparing mild brain injury vs. severe brain injury  normal body weight; #: P < 0.05 comparing mild brain injury vs. severe brain injury  low body weight; y:
P < 0.05 comparing severe brain injury  normal body weight vs. severe brain injury  low body weight based on post hoc comparison after one-way ANOVA. HI: hypoxic-ischemic;
grip strength normalized to body weight (g/g).the CBP treatment group versus the saline control group (Fig. 3E and F).
3.9. Effect of CBP treatment on osteoblast differentiation
To determine the role of CBP in severely brain-injured mice
with bone loss, markers associated with osteoblast differentiation,5
saline control group (P = 0.001; Fig. 3I and J).
4. Discussion
From clinical discovery, insufficient mechanical loading affect-
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iscovery of the main factors in this translational research became
he basis for the development of a mouse model of CP with bone
oss.
In the clinical study, ambulatory function was most associated
ith lumbar and femur bone density, and body weight was an
nfluential factor for determining femur bone density. Non-
mbulatory CP participants showed significant bone loss, espe-
ially those who were underweight. From previous clinical studies
6,23,24], these two clinical parameters were considered reason-
ble factors for developing a mouse model of CP with bone loss.
Similar to the clinical study, the factors most affecting skeletal
one loss in the mouse model of CP with neonatal HI brain injury
ere increased brain injury severity and low body weight
6,23]. Because these results match clinical findings, the transla-
ional research hypothesis of a complex interplay of severe brain
njury, low body weight, insufficient mechanical loading, and
educed muscle force affecting overall bone health in the mouse
odel of CP was supported. The osteoporotic condition was clearly
haracterized by reduced BMD based on the severity of brain insult
nd the loss of body weight in the mouse model of CP.
Humans and mice have fundamentally different biomechanical
oading conditions. Humans primarily engage in upright and
ipedal movement, with their weight distributed along the
raniocaudal axis, whereas mice primarily engage in quadrupedal
ovement. Individuals with CP showed obvious non-ambulatory
unction after severe brain injury, although mice maintained
ocomotor function [25,26]. In individuals with CP, ambulatory
unction was strongly associated with femur density and lumbar
pine density. In the mouse model of CP, injury severity affected
he whole body and lumbar spine density the most, and body
eight affected the femur and humerus density the most. In the
resent study, the factors examined exerted different effects on
one density likely due to the specific types of movement that
umans and rodents engage in.
that the mechanism of biomineralization by hyper-gravity was
attributed to osteopontin expression with enhanced RUNX2
expression. Osteopontin is a non-collagenous protein translated
by SPP1 and contains a collagen-binding motif and arginine-
glycine-aspartate (RGD) motif. The CBP exerts biomineralization
by binding collagen fibrils with a strong affinity and RGD induces
bone resorption [18,28–30]. A synthesized CBP of osteopontin was
an effective anti-osteoporotic agent that facilitated osteogenesis in
an ovariectomized murine model of postmenopausal bone loss
[19]. The CBP has been suggested as an anti-osteoporotic agent
based on the underlying mechanism of osteogenesis and anti-
adipogenesis [19,31]. Therefore, administering CBP to the mouse
model of CP with bone loss was reasonable based on the
transcriptome analysis and BMD assessments in human subjects.
Non-ambulatory individuals with CP exhibit abnormal bone
change owing to limited mechanical loading showing profound
underdevelopment of trabecular microarchitecture [32]. Further-
more, chronic limitations in physical mobility aggravate abnormal
symptoms over time, thereby resulting in atypical fractures
[33]. Therefore, we expected evidence of skeletal bone loss in
patients with CP in this study because these patterns were recently
demonstrated [3,34].
However, a remarkable decrease in SPP1 expression in CP,
which results in bone loss as compared with normal adults, was
not previously documented in individuals with CP. Therefore, this
significant result provided the rationale to implement a novel
therapeutic approach by using a synthesized CBP involved in
biomineralization in a mouse model of CP with bone loss as a
preclinical study.
Before CBP administration, inclusion and exclusion criteria
were first used in the mouse model of CP based on 2 main factors:
injury severity and body weight. As compared with normal mice,
severely HI brain-injured mice with low body weight showed
decreased total collagen content relative to corresponding bone
areas including trabecular and cortical bone. However, osteopo-
able 4
actors associated with skeletal BMD in a mouse model of CP (n = 24).
BMD region Variables (reference) Univariate analysis Multivariate analysis
Coefficient (SE) P-value Coefficient (SE) P-value
Whole body Sex (female) 0.0004 (0.0030) 0.9049 – –
Body weight 0.0012 (0.0002) < 0.0001* – –
Injury severity (mild) 0.0108 (0.0019) < 0.0001* 0.0108 (0.0019) < 0.0001*
Grip strength 0.0003 (0.0001) 0.0108* – –
Rearing activity 0.0003 (0.0001) 0.0198* – –
Lumbar spine Sex (female) 0.0059 (0.0050) 0.2551 – –
Body weight 0.0017 (0.0005) 0.0022* – –
Injury severity (mild) 0.0176 (0.0036) 0.0001* 0.0176 (0.0036) 0.0001*
Grip strength 0.0005 (0.0002) 0.0161* – –
Rearing activity 0.0003 (0.0002) 0.0964 – –
Affected femur Sex (female) 0.0069 (0.0053) 0.2091 – –
Body weight 0.0024 (0.0004) < 0.0001* 0.0024 (0.0004) < 0.0001*
Injury severity (mild) 0.0184 (0.0039) 0.0001* – –
Grip strength 0.0005 (0.0002) 0.0077* – –
Rearing activity 0.0005 (0.0002) 0.0151* – –
Affected humerus Sex (female) 0.0014 (0.0030) 0.6411 – –
Body weight 0.0013 (0.0002) < 0.0001* 0.0013 (0.0002) < 0.0001*
Injury severity (mild) 0.0106 (0.0019) < 0.0001* – –
Grip strength 0.0003 (0.0001) 0.0066* – –
Rearing activity 0.0003 (0.0001) 0.0050* – –
E: standard error; R2 = 0.604, adjusted R2 = 0.586 in the whole-body BMD analysis; R2 = 0.520, adjusted R2 = 0.498 for lumbar BMD; R2 = 0.656, adjusted R2 = 0.640 for affected
mur BMD; R2 = 0.653, adjusted R2 = 0.637 for affected humerus BMD; *: P < 0.05 based on linear regression analyses.In the transcriptome analysis, SPP1 expression was significantly
ownregulated in individuals with CP who had bone loss as
ompared with normal adults. Thus, bone metabolism in people
ith CP may be unbalanced due to accumulative lifelong motor
mpairments. Insufficient mechanical stimuli in individuals with
P can impede bone remodelling. Zhou et al. (2015) [27] suggested6
rotic mice in this study showed bone anabolic effects, exhibiting
increased total collagen content after long-term CBP treatment as
compared with the saline control group. Osteopontin is essential
for type-I collagen secretion [35]. Osteopontin mRNA levels were
also downregulated in bone-marrow stromal cells from hind-limb
disuse in tail-suspended rats as compared with the normal control
Figure 3. The CBP treatment protected against bone loss in a mouse model of CP. A. A representative 3-D image of femur. B. Trabecular thickness based on micro-CT (mCT)
analysis. C. Representative Masson’s trichrome for collagen staining. D. Quantification of total collagen to the corresponding area. E and F. Enhanced bone turnover markers
PINP and CTX-I were identified in the CBP treatment group compared with the saline control group. G–J. Levels of osteoblast differentiation markers RUNX2 and OCN in the
CBP treatment group compared with the saline control group. Data are mean  SD. A and B. Sample size (group in the femur analysis, saline, n = 6; CBP, n = 6; group in the
humerus analysis, saline, n = 7; CBP, n = 5); *: P < 0.05 based on independent t-test. C and D. Sample size (normal, n = 6; saline, n = 6; CBP, n = 6); scale bar is 500 mm; *:
P < 0.05 based on post hoc comparison after one-way ANOVA. E and F. Sample size (saline, n = 16; CBP, n = 24); PINP, N-terminal propeptide of type I procollagen; CTX-I, C-terminal
telopeptide of type I collagen; *: P < 0.05 based on independent t-test. G and H. Scale bar (left: 500 mm; right: 100 mm); RUNX2, runt-related transcription factor 2; sample size
(saline, n = 6; CBP, n = 6); immunoreactivity defined as the ratio of optical density (OD) of immunoreaction sites within the trabecular area. I and J. Scale bar (left: 500 mm; right:
200 mm); OCN, osteocalcin; sample size (saline, n = 6; CBP, n = 6).
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ith osteopontin expression via mechanical stress in the bone
emodelling matrix [37]. On the basis of mCT analysis, the bone
orphometrical index of trabecular thickness and 3-D images also
emonstrated unhealthy trabecular microstructures in the mouse
odel of CP. However, CBP treatment significantly improved
rabecular thickness in the affected limbs, including femur and
umerus.
Bone turnover activity can be altered in individuals with CP, as
videnced by abnormal serum or urine levels of bone formation
nd bone resorption markers as compared with normal levels. In
articular, increased level of the bone resorption marker, CTX-I, is
bserved [38,39]. Therefore, antiresorptive drugs such as bisphos-
honates have been used because of their efficacy in reversing
xcessive CTX-I level in individuals with CP. However, potentially
erious adverse events such as atypical femur fractures are
xpected when the medications are used for a long time in
iddle-aged people with CP. In addition, consensus regarding
reatment initiation, standardized regimen, and treatment cessa-
ion is lacking [40–43].
Unlike bisphosphonates, long-term CBP treatment led to
nhanced bone turnover activity in our mouse model of CP with
one loss. Both bone formation and bone resorption was
ignificantly increased in the CBP treatment than saline control
roup. Although bone turnover markers are difficult to interpret,
ncreased bone turnover activity indicates that CBP treatment was
ffective in facilitating bone remodelling in the mouse model of CP.
Consistent with the previous study [19], CBP treatment
ncreased the expression of RUNX2, the first transcription factor
n the early phase of osteoblast differentiation [44]. OCN expres-
ion was also highly enhanced by CBP treatment, regulating
steoblast differentiation and osteoblast maturation in the mouse
odel of CP with bone loss. Thus, CBP-induced osteogenesis and
one remodelling are linked to biomineralization.
. Conclusions
From the clinical outcomes of people with CP, in this
ranslational research, a mouse model of CP with bone loss was
eveloped to mimic human disease conditions from bedside to
ench. From the transcriptome analyses in human PBMCs, the top-
anked gene SPP1 was utilized to synthesize the CBP. Anabolic
ffects of CBP treatment were shown in severely HI brain-injured
ice with low body weight. The present study calls for a human
rial to provide clinical insights into using CBP medication for
reating bone loss in individuals with CP.
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